Lawmakers signal willingness to counter China’s biotech gains

Lawmakers Signal They'll Act on China's Grip on America's Drug Supply

The House Select Committee on the Chinese Communist Party held a hearing Wednesday on what lawmakers of both parties have increasingly called a national security vulnerability: the United States' dependence on China for the building blocks of its generic drug supply. The hearing, titled "From the Science Lab to the Medicine Cabinet: How China is Cornering the Market on Our Medicines," took place as bipartisan momentum in Congress has started to move beyond hearings into actual legislation.

China controls approximately 90 percent of the global supply of key starting materials (KSMs) used to make active pharmaceutical ingredients (APIs) in generic drugs, according to testimony and reporting cited in a Senate-related briefing this week. That concentration — described by at least one Congressional observer as "perfectly designed for catastrophic failure" — has drawn bipartisan concern that has so far produced more investigations than solutions.

The Senate Commerce Committee held a separate, earlier hearing this week where members from both parties expressed alarm over America's dependence on China for essential medicines and the ingredients required to make them. That hearing, reported by Forbes on Tuesday, drew relatively little attention from major healthcare industry commentators — a fact that itself struck some observers as noteworthy given the stakes.

Wednesday's House Select Committee hearing featured four witnesses: Dr. Jacob Becraft, CEO of Strand Therapeutics; Patrick Cashman, president of USAntibiotics; Francisco Gimenez, partner at 8VC; and Dr. Marta E. Wosińska, a senior fellow in economic studies at the Brookings Center on Health Policy.

Separately, the legislative response has started to take shape. Senators Todd Young (R-Ind.) and Ben Ray Luján (D-N.M.) introduced the AI-Ready Bio-Data Standards Act this week, directing the National Institute of Standards and Technology to establish standards for biological data to support American competitiveness in the convergence of AI and biotechnology. Companion legislation was introduced in the House by Representatives Ro Khanna (D-Calif.) and Jay Obernolte (R-Calif.). Young chairs the National Security Commission on Emerging Biotechnology.

"High-quality biological data has become a strategic asset in the global tech competition, yet the United States currently lacks the digital infrastructure and national standards needed to ensure our researchers and innovators have world-class biological datasets," Young said in a statement. "Conversely, China has recognized the importance of this data and made it a priority, often at the expense of the U.S."

The bill is a narrower response than what many advocates want — it addresses data standards, not the structural dependence on China for pharmaceutical ingredients. But it reflects a growing consensus in Congress that the issue requires a legislative answer, not just another study.

The urgency is compounded by events elsewhere. A standoff in the Strait of Hormuz — the critical shipping lane through which petrochemical inputs flow to Indian pharmaceutical manufacturers — has raised fresh concern about the fragility of the generic drug supply chain. India supplies roughly 47 percent of generic prescriptions dispensed in the U.S. by volume, and Indian manufacturers depend on Gulf logistics hubs for many chemical inputs from China. Air cargo rates from India have reportedly risen 200 to 350 percent for some routes, according to supply chain analysts cited by CNBC. Most pharmacies and wholesalers operate on a just-in-time inventory model for generics, meaning sustained disruption could start showing up for consumers within four to six weeks.

USAntibiotics, represented at Wednesday's hearing by Cashman, is one of the few domestic manufacturers attempting to reshore antibiotic production. The company has argued that the economics of generic manufacturing have made it nearly impossible to compete with Chinese producers without meaningful policy support — tariff protection, long-term procurement commitments, or some combination.

The Select Committee hearing comes as the Senate has also been active on pharmaceutical supply chain issues, with bipartisan concern expressed about limited visibility into KSM supply chains and the fact that over 40 percent of generic drugs sold in the U.S. have a single manufacturer. Several senators pressed for action rather than continued monitoring.

What's clear is that the coalition of lawmakers willing to push back against China's pharma dominance has widened. What's less clear is whether the legislative package that emerges will be proportionate to the scale of the problem — or whether it will end up, like so many supply chain reports before it, as a document that gets cited rather than implemented.